CAT Catco Reinsurance Opportunities Fund Limited

RNS Number:0998F
Cambridge Antibody Tech Group PLC
23 June 2006



                Cambridge Antibody Technology Group plc ("CAT")


CAT (LSE: CAT; NASDAQ: CATG) announces that, following the recommended offer
made by AstraZeneca UK Limited for CAT becoming unconditional in all respects on
22 June 2006, G H R Musker, S F Grady, I M D Brimicombe and A C N Kemp were
appointed Directors of CAT with effect from 22 June 2006. No further information
is required to be disclosed pursuant to Listing Rule 9.6.13.

For further information please contact:

Rowena Gardner, Director of Corporate Communications

+44 (0) 1223 898 622




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAAKNKBQBKDKAB

Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024